AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02068391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Program
Description: The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
Study NCT02068391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
Study NCT02068391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
Study NCT01362062 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Study NCT03703609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
Study NCT03804476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER-271
Description: AER-271, the test article for this study.
Study NCT03804476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for this study.
Study NCT03223649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Bouts
Description: Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
Study NCT03223649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: (Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
Study NCT00331058 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopsy
Description: Healthy and Asthmatic Volunteers
Study NCT00331058 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prednisolone
Description: Asthmatic Volunteers
Study NCT00444639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl®)
Description: Two injections of 11.25mg given every 12 weeks
Study NCT00444639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin (Decapeptyl®)
Description: Two injections of 11.25mg given every 12 weeks
Study NCT04930133 — intervention group
Intervention type: DRUG
Intervention: Gilotrif
Description: This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
Study NCT01944163 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Applying a referral model
Description: GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
Study NCT00059592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Study NCT06066073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distal Water
Description: The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
Study NCT04527939 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: three-dimensional endorectal ultrasonography
Description: three-dimensional endorectal ultrasonography
Study NCT04527939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three-dimensional endorectal ultrasonography
Description: three-dimensional endorectal ultrasonography
Study NCT05354193 — intervention group
Intervention type: OTHER
Intervention: vasoplegic syndrome
Description: In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock
Study NCT00931801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir/raltegravir
Description: Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
Study NCT00931801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir/raltegravir
Description: Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
Study NCT00931801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/tenofovir/emtricitabine
Description: Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
Study NCT02479256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Placebo
Description: Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
Study NCT02479256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
Study NCT02479256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate placebo
Description: Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
Study NCT01923454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracentesis
Description: At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
Study NCT01923454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
Study NCT01923454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral iridotomy
Description: All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
Study NCT02214745 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire developed for this purpose by the investigators
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 0.3 mg, once daily, 1 day
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 1.0 mg, once daily, 1 day
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 3 mg, once daily, 1 day
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 10 mg, once daily, 1 day
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 30 mg, once daily, 1 day
Study NCT01110382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
Study NCT01110382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
Study NCT01110382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
Study NCT01110382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
Study NCT01110382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study NCT03574740 — intervention group
Intervention type: OTHER
Intervention: Tobacco Smoking
Description: Influence of Tobacco Smoking on the development of OSA
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC
Study NCT00265018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Study NCT00265018 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 30 Gy IF-RT
Study NCT00265018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Gy IF-RT
Study NCT00265018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 Gy IF-RT
Study NCT03519061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Nasal saline irrigations with budesonide
Study NCT02580786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer support
Study NCT01714258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac output measurement
Description: non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral , 75 mg, once daily, 1 day
Study NCT03420105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological, psycho-pathological and quality of life assessments
Description: Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
Study NCT03420105 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hormonotherapy
Description: Adjuvant hormone therapy
Study NCT02738333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT01802333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03166605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Giving simethicone before and after capsule ingestion.
Study NCT03166605 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Simethicone
Description: Giving simethicone before and after capsule ingestion.
Study NCT02110407 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT02110407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT01267175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X54 insulin pump with low suspend feature
Description: Change from current insulin pump to new X54 pump
Study NCT02738333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT02738333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
Study NCT00278109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: chemotherapy
Study NCT00278109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: doxorubicin
Study NCT03576313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DP)
Description: DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
Study NCT03576313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin (IVM)
Description: IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
Study NCT03576313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard malaria control interventions only
Description: this is the standard malaria control interventions in the Gambia
Study NCT03576313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard malaria control interventions only
Description: this is the standard malaria control interventions in the Gambia
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine is an anti-inflammatory and immunosuppressive drug
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine's placebo
Description: Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
Study NCT00278109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine's placebo
Description: Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan's placebo
Description: Ambrisentan's placebo is similar to Ambrisentan in form and dosage
Study NCT04528056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan's placebo
Description: Ambrisentan's placebo is similar to Ambrisentan in form and dosage
Study NCT04104880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
Study NCT00922805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: guar gum
Description: guar gum (20 g/l of formula) for one week
Study NCT01423916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712 (4mg)
Description: Arms assigned to this intervention receive 4mg.
Study NCT01423916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Arms assigned to this intervention will receive 400mg.
Study NCT01423916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712 (12mg)
Description: Arms assigned to this intervention receive 12mg.
Study NCT01423916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-34712 placebo
Study NCT02414620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generation II Dental Vibe Unit
Description: . The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
Study NCT02553538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Study NCT02133365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and Interoceptive Exposure
Description: The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
Study NCT02087722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KI1001
Study NCT02087722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04035746 — intervention group
Intervention type: OTHER
Intervention: Observation of microcirculation and plasticity of the brain
Description: Assessment of microcirculation, brain plasticity and clinical function
Study NCT03191253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-appropriate meals and groceries
Description: Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.